SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-07-17
👔
Gain Therapeutics, Inc.
@GANX_InsiderForm 4 Filing: Melincoff Gwen A Acquires (Grant) shares of $GANX
STOCK AWARD / GRANT
⚡ MATERIALITY: 1/10
corporate issuer
Gain Therapeutics, Inc.
Ticker: $GANX
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-07-15
Shares: 25,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Melincoff Gwen A, holds the title of Director at Gain Therapeutics, Inc..
On 2026-07-15, the insider transacted 25,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Melincoff Gwen A (Director) was granted $0 of $GANX
Post-Transaction Position: 25,000 shares
SEC Accession No: 0001104659-26-084435 (CIK: 1614890)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.